1:48 PM
 | 
Jul 19, 2018
 |  BC Extra  |  Clinical News

Allergan's abicipar pegol non-inferior to Lucentis, but increases inflammation

Allergan plc (NYSE:AGN) and Molecular Partners AG (SIX:MOLN) said both dosing regimens of abicipar pegol (AGN-150998) met the primary endpoint of non-inferiority to Lucentis ranibizumab in the proportion of patients with stable vision at week 52 in a pair of Phase III trials to treat neovascular age-related macular degeneration (AMD). However, the candidate led to a greater incidence of intraocular inflammation compared with Lucentis.

The news sent shares of Molecular Partners down CHF4.26 (19%) to CHF18.14 on Thursday.

The SEQUOIA and CEDAR trials...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >